Treatment Efficacy of Mindfulness-based Cognitive Therapy for Distress in Advanced Cancer Patients

NCT ID: NCT05768256

Last Updated: 2023-04-05

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-03-28
• Study Completion Date: 2024-02-29

Brief Summary

'Distress' refers to emotional distress, including psychological distress, in cancer patients. This study aims to explore whether mindfulness-based cognitive-behavioral therapy for cancer patients is effective in relieving distress and to discover neurophysiological factors that contribute to relieving distress. Mindfulness meditation, which is the core of mindfulness-based cognitive behavioral therapy, can develop cognitive flexibility through 'awareness of what is happening now'. In this study, a mindfulness-based cognitive behavioral therapy program is implemented for patients with advanced cancer, and clinical characteristics and conditions including distress level are observed through questionnaires and interviews. In addition, genetic data and brain imaging data are collected through blood sampling and brain magnetic resonance imaging. The ultimate goal of this study is to prove the therapeutic efficacy of a mindfulness-based cognitive behavioral therapy program for distress of patients with advanced cancer through an in-depth and multifaceted integrated approach, and to understand the related neurophysiological mechanisms.

Detailed Description

The number of subjects participating in this study is up to 40 advanced cancer patients. The research subject is responsible for the medical expenses incurred in the usual standard medical procedures, and the researcher is responsible for the examination expenses (brain magnetic resonance imaging, blood sampling) performed by participating in other studies.

This study runs until Feb 01, 2024. After enrolling in the study, patients with advanced cancer participate in mindfulness-based behavioral therapy once a week for eight weeks. All research subjects participating in this study will have an interview to collect basic information, fill out a questionnaire for index evaluation, blood collection, and brain magnetic resonance imaging. Participants participating in this study will receive specific evaluations as follows.

1. Interview to gather basic information: demographic information, (if applicable) psychiatric symptoms and treatment-related information are collected.

2. Filling out questionnaires for psychological evaluation and behavioral data collection: 4 times [Baseline, 2 weeks later, 4 weeks later, 8 weeks later (Post-treatment)], Psychiatry Fill out a questionnaire to comprehensively evaluate your symptoms and psychological state.

3. Blood collection: 6ml of blood is collected twice before and after treatment.

4. Brain Magnetic Resonance Imaging: Make an appointment and visit the examination room in the hospital to perform a total of 2 times before and after treatment.

Clinical symptom and progress data are collected if patients have previously been treated at this hospital, and medical information that occurs after study registration is collected every one month during the study participation period.

Distress Indicators

• 2022 NCCN Guidelines for Distress Management's Korean version of Distress Thermometer (DT) and Problem List (PL)
• Perceived Stress Scale-4 (PSS-4) Indicators of depression and anxiety characteristics
• Brief Edinburgh Depression Scale (BEDS)
• Beck Depression Inventory-ll (BDI-ll)
• Beck Anxiety Inventory (BAI)
• Hospital Anxiety and Depression Scale (HADS) Mindfulness Characteristics and Symptom Related Indicators
• Toronto Mindfulness Scale (TMS)
• Self-Compassion Scale-Short Form (SCS-SF)
• Demoralization Scale-II (DS-II-Kr)
• Thought-Action Fusion Scale (TAFS) Quality of life and resilience indicators
• Functional Assessment Cancer Therapy-General (FACT-G)
• WHO Quality of Life-BREF (WHOQOL-BREF)
• The Brief Resilience Scale (BRS) Epigenetic data
• DNA methylation analysis flow DNA preparation → uracil change of non-methylated cytosine using bisulfate → amplification using PCR → methylation detection by methylation specific PCR
• Selection of candidate genes - Experience in prior research on OXTR and FKBP5gene → Application to same gene methylation studies Brain imaging data
• Acquisition of magnetic resonance imaging (MRI) - structural imaging (T1), functional imaging (fMRI), diffusion tensor imaging (DTI)

Conditions

Cancer Pain; Cancer; Distress, Emotional; Therapy-Associated Cancer; Psychiatric or Mood Diseases or Conditions; Psychological Distress

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Advanced cancer patients

Group Type: EXPERIMENTAL

Mindfulness-Based Cognitive-behavioral Therapy for Distress

Intervention Type: BEHAVIORAL

Mindfulness-based cognitive-behavioral therapy, MBCT, is a modified form of cognitive-behavioral therapy that incorporates mindfulness practices that include present moment awareness, meditation, and breathing exercises. Advanced cancer patients will participate in the study until the end of the study (Feb 2024). After registering for the study, the study subjects receive mindfulness-based cognitive behavioral therapy once a week for eight weeks.

Interventions

Mindfulness-Based Cognitive-behavioral Therapy for Distress

Mindfulness-based cognitive-behavioral therapy, MBCT, is a modified form of cognitive-behavioral therapy that incorporates mindfulness practices that include present moment awareness, meditation, and breathing exercises. Advanced cancer patients will participate in the study until the end of the study (Feb 2024). After registering for the study, the study subjects receive mindfulness-based cognitive behavioral therapy once a week for eight weeks.

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

• A person diagnosed with gastric cancer, colon cancer, lung cancer, liver cancer, breast cancer, cervical cancer, prostate cancer, or other cancers from a doctor, and a advanced cancer patient with a cancer stage of 2 to 4
• Those who wish to participate in the Mindfulness-Based Cognitive Behavioral Treatment for distress (MBCT-D) program

Exclusion Criteria

• A person with a history of neurological disease, head trauma accompanied by loss of consciousness, brain metastasis of cancer, and mental retardation (IQ<70).
• Pregnant and lactating
• If the symptoms are severe or the reality testing ability and judgment are considered to be significantly deteriorated through a mental health examination by a psychiatrist
• A person who is determined to be at risk of serious suicide or violent behavior in the mental state test
• A foreigner (a non-Korean person)
• A person who is illiterate in Korean
• A left-handed person
• A person who has previously experienced mindfulness-based cognitive behavioral therapy
• A person who the researcher determines that it is inappropriate to participate in clinical research for other reasons

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

CHA University

OTHER

Sponsor Role: lead

Responsible Party

Chun Il Park

Associate Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

CHA Bundang Medical Center

Seongnam-si, Kyeonggi-do, South Korea

Countries

South Korea

References

Wurtzen H, Dalton SO, Elsass P, Sumbundu AD, Steding-Jensen M, Karlsen RV, Andersen KK, Flyger HL, Pedersen AE, Johansen C. Mindfulness significantly reduces self-reported levels of anxiety and depression: results of a randomised controlled trial among 336 Danish women treated for stage I-III breast cancer. Eur J Cancer. 2013 Apr;49(6):1365-73. doi: 10.1016/j.ejca.2012.10.030. Epub 2012 Dec 19.

Reference Type: BACKGROUND

PMID: 23265707 (View on PubMed)

Kim B, Lee SH, Kim YW, Choi TK, Yook K, Suh SY, Cho SJ, Yook KH. Effectiveness of a mindfulness-based cognitive therapy program as an adjunct to pharmacotherapy in patients with panic disorder. J Anxiety Disord. 2010 Aug;24(6):590-5. doi: 10.1016/j.janxdis.2010.03.019. Epub 2010 Apr 3.

Reference Type: BACKGROUND

PMID: 20427148 (View on PubMed)

Other Identifiers

NRF-2021R1I1A1A01048880

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

CHAMC 2022-12-050

Identifier Type: -

Identifier Source: org_study_id